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ABSTRACT
Potchefstroom experienced an outbreak of Neisseria meningitidis (N. meningitidis) during May-July 2003. An oppor-
tunity for obtaining valuable data arose when mass prophylactic treatment to approximately 28% of the Potchefstroom
community was provided by the Department of Health, North-West Province. The aim of this study was to investi-
gate the prevalence of side-effects experienced by staff and students of the Potchefstroom University for Christian
Higher Education (PU for CHE) who received a single prophylactic dose of oral ciprofloxacin 500 mg between 23 and
29 July 2003. Information gained from the Potchefstroom outbreak may be valuable for the future management of
similar outbreaks in other communities. Various stakeholders have published related reports, protocols, recom-
mendations and guidelines, which mostly focused on the prevention, management and control of meningococcal
disease. Very little has been reported about the side-effects experienced, especially in cases where ciprofloxacin
500 mg single dose had been dispensed. One or more side-effects were reported by 24.2% of the participants, while
5.4% had to consult with a health care worker due to the severity of side-effects resulting from a single dose.
Practical significance could not be demonstrated for any of the side-effects reported after single versus multiple
doses nor when the effects of gender or requirement for medical consultation were tested.
OPSOMMING
‘n Uitbraak van Neisseria meningitidis (N. meningitidis) gedurende Mei-Julie 2003 en die daaropvolgende verskaffing
van massa-profilakse deur die Departement van Gesondheid, Noordwesprovinsie aan ongeveer 28% van die plaaslike
gemeenskap het ‘n geleentheid geskep om waardevolle inligting in te win. Die doel van die studie was om die
voorkoms van newe-effekte te ondersoek wat deur die personeel en studente van die Potchefstroomse Universiteit
vir Christelike Hoër Onderwys ervaar is na toediening van ‘n enkel profilaktiese dosis van siprofloksasien 500 mg
tussen 23-29 Julie 2003. Inligting wat hieruit voortspruit mag waardevol wees tydens toekomstige bestuur van
uitbrake in ander gemeenskappe. Verskillende belanghebbendes het verslae, protokolle, aanbevelings en riglyne
gepubliseer, wat meestal op die voorkoming, bestuur en beheer van meningokokkale siekte gefokus het. Daar is
egter min gerapporteer oor die newe-effekte wat ondervind is veral waar siprofloksasien 500mg enkeldosis toegedien
is. Een of meer newe-effekte is deur 24.2% van die deelnemers  ervaar en 5.4% het dit nodig geag om ‘n
gesondheidswerker te konsulteer in verband met die newe-effekte wat ervaar is. Geen prakties betekenisvolle
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verskille is aangedui indien die effeksgrootte bereken is vir die newe-effekte getoets tussen die enkeldosis versus
die meervoudige dosis nie, selfs ook nie nadat die effek van geslag of konsultasie getoets is nie.
INTRODUCTION
“Few infections can cause the civil, medical, and so-
cial stress that occurs when serious meningococcal
disease enters a community” (Apicella, 1995:2).
Meningitis is an inflammation of the meninges (the
membranes surrounding the brain and spinal cord).
Meningitis can be caused by either bacterial or viral
infection. Various bacteria can induce meningitis but
the most common causes of the reported cases were
N. meningitidis (meningococcus) and Streptococcus
pneumoniae (pneumococcus) (Beers & Burkow,
2003:1). Until recently, Haemophilus influenzae type b
was the most common cause of meningitis in children
older than one month, but vaccination dramatically re-
duced the incidence (Beers & Burkow, 2003:1). Menin-
gococcus is a serious life-threatening condition that
requires immediate medical treatment.
N. meningitidis causes both sporadic disease and out-
breaks all over the world. Various reports, protocols,
control measures, guidelines, recommendations and
policy strategies have been drafted and implemented
in order to control and manage the disease (American
Academy of Pediatrics, 2000:1500; Centers for Dis-
ease Control and Prevention (CDC), 2000:11; Canada
Communicable Disease Report, 1994:1825). These
mostly deal with the prevention, management and con-
trol of meningococcal disease. Very little was reported
in these publications about the medication side-effects,
especially in cases where a single dose of ciprofloxacin
500 mg was dispensed.
Since 1991, the frequency of localised outbreaks of N.
meningitidis in the United States of America (USA) in-
creased, especially among college students and re-
cruits in the military. Students, recruits and other mili-
tary staff living in crowded conditions experience an
increased risk for meningococcal infection. For this
reason, a vaccine that is protective against four types
(A, C, W-135, Y) of N. meningitidis is given to basic
trainees and college freshmen, particularly those who
live in dormitories (CDC, 2000:11).
STUDY PURPOSE AND RATIONALE
The purpose of this study was to investigate the preva-
lence of side-effects experienced by staff and students
of the Potchefstroom University for Christian Higher
Education (PU for CHE), now the Potchefstroom cam-
pus of the North-West University) who received a single
prophylactic dose of oral ciprofloxacin 500 mg between
23 and 29 July 2003. The efficacy of ciprofloxacin
chemoprophylaxis is not disputed or questioned, the
side-effects are well reported in various recognised phar-
macological literature. However, very little was reported
about the side-effects experienced in cases where
ciprofloxacin 500 mg single dose was administered.
Eight confirmed cases of meningitis were reported in
the greater Potchefstroom district from May – 30 July
(Joint Task Team: Provincial and Local Health Authori-
ties and PU for CHE, 2003c). Five confirmed cases
were of students from different tertiary institutions in
the city. Three students died and two were treated and
discharged from hospital (Joint Task Team: Provincial
and Local Health Authorities and PU for CHE, 2003a).
Two of the deceased students were from the PU for
CHE and they passed away on 23 July (PU for CHE,
2003) and 27 July 2003 respectively (Joint Task Team:
Provincial and Local Health Authorities, World Health
Organisation (WHO) and the Potchefstroom University,
2003b).
A joint task team headed by doctor TGK Oosthuizen
(Chief Director Health Service Delivery, Department of
Health, North-West Province) was formed by 28 July
2004 and a decision was made to dispense mass
ciprofloxacin 500 mg tablets on 28 July 2003 between
16:00 and 22:00 to staff and students of all the tertiary
institutions in the city (Joint Task Team: Provincial and
Local Health Authorities and the PU for CHE, 2003c).
The rationale was to attempt a simultaneous mass eradi-
cation of the N. meningitidis bacteria in the population
of possible carriers of these bacteria.
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An opportunity arose to gather data concerning the
prevalence of side-effects after a single prophylactic
dose of oral ciprofloxacin 500 mg was administered on
such a large scale and the focus of this investigation
was only on the staff and students of the PU for CHE
(Potchefstroom campus) in the time period 23-29 July
2003.
PROPHYLACTIC TREATMENT OF MEN-
INGITIS
Chemoprophylaxis is highly effective in some clinical
settings and in others it is totally without value and
may be deleterious. The use of antimicrobial compounds
to prevent infections remains controversial in several
situations (Chambers, 2001:1164). The purpose of
chemoprophylaxis is to eradicate nasopharyngeal
colonisation by N. meningitidis, which prevents the dis-
ease in contacts and its transmission to non-immune
susceptible people. Chemoprophylaxis is not effective
in preventing a disease once invasion of tissue has taken
place (Canada Communicable Disease Report,
1994:1826).
A comprehensive report was published by the Cana-
dian Paediatric Society (CPS), Infectious Diseases and
Immunization Committee, American Academy of Pedi-
atrics (AAP) and the Committee on Infectious Diseases
in 1997, which was reaffirmed in February 2003, in which
they addressed meningococcal disease prevention and
control strategies for practice-based physicians.  In their
joint statement they stressed that chemoprophylaxis
is indicated for close contacts of all persons with inva-
sive meningococcal disease, whether sporadic, or in a
cluster or outbreak. The CPS and the AAP currently
recommend antimicrobial chemoprophylaxis for con-
tacts of persons with invasive meningococcal disease,
including household members, individuals in childcare
centres and nursery schools, and persons directly ex-
posed to oropharyngeal secretions through kissing or
sharing of food or beverages during the seven days
before the onset of disease in the index case. Prophy-
laxis is not recommended routinely for medical per-
sonnel except for those who have had intimate expo-
sure, such as that which occur with mouth-to-mouth
resuscitation, intubation or suctioning. The index case
should also receive chemoprophylactic antibiotics be-
fore discharge unless treated with ceftriaxone. Because
the attack rate of secondary disease after a close con-
tact is highest in the few days following the onset of
disease in the primary case, the delay in providing an-
timicrobial chemoprophylaxis must be minimised and,
ideally, the prophylaxis should be given within 24 hours
of case identification. Suggested chemoprophylaxis
regimens include rifampin (rifampicin), ceftriaxone and
ciprofloxacin and these are shown in Table 1.
Various health departments (Welsh Medicines Informa-
tion Centre, 2003:5; Massachusetts Department of
Public Health, 1999:7) follow similar guidelines as re-
flected in Table 1 for chemoprophylaxis but for preg-
nant women they also include Ceftriaxone 250 mg as a
single dose, administered intramuscularly.
The WHO provided chemoprophylactic guidelines simi-
lar to those reflected in Table 1, but also included
spiramycin or minocycline for five days as alternatives
(WHO, 1998:28). Their report did not recommend mass
chemoprophylaxis to prevent or control epidemics.
Oral rifampicin had been the drug of choice for chemo-
prophylaxis in recent decades. Rifampicin is 72% to
90% effective in eradicating nasopharyngeal carriage
and serious adverse effects with short-term therapy are
rare. Urine and stools may be stained orange or red
and soft contact lenses may become tinted and there-
fore warnings would be required. Rifampicin may also
interfere with the efficacy of oral contraceptives and is
not recommended for use during pregnancy. The im-
pact of rifampicin on the metabolism of other medica-
tions such as those for seizure prevention and antico-
agulation must also be considered. Ceftriaxone admin-
istered as a single intramuscular dose is an alternative
to rifampicin and is more than 95% effective in eradi-
cating carriage. In adults who are not pregnant, a single
dose of ciprofloxacin is an effective oral alternative to
rifampicin in 90% to 95% of cases. Although
ciprofloxacin is used in children for chemoprophylaxis
of meningitis, it is not currently approved for use in chil-
dren younger than 18 years and should not be used
when safer alternatives are available (CPS, 1997:5; Petri,
2001:1182). Although sulphonamides were effective in
preventing disease for many years, the majority of iso-
lates of N. meningitidis of serogroups B and C in the
USA as well as group A isolates from other countries
are now resistant (Petri, 2001:1172).
CIPROFLOXACIN
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* Not for use by pregnant women.
Information in Table 1, taken from a joint report of the Canadian Paediatric Society (CPS), Infectious Disease and Immunization Committee, American Academy of Pediatrics (AAP) and the Committee
on Infectious Diseases, 1997.
Table 1: Recommended chemoprophylaxis regimens for high-risk contacts and index cases of invasive
meningococcal disease
Single dose ciprofloxacin was shown to be effective in
eradicating pharyngeal carriage of N. meningitidis by
Gaunt and Lambert (1988:489) when 2100 navy per-
sonnel received single oral doses of ciprofloxacin 500
mg and 570 of the personnel were swabbed 2-4 days
later. An additional 277 personnel members were fol-
lowed-up for nine weeks afterwards to determine the
elimination rate of the pharyngeal carriage. The overall
prevalence of carriage declined from 19% to less than
1.5% as a result of the use of ciprofloxacin.
Ciprofloxacin is one of a number of fluorinated 4-
quinolones and is of great importance therapeutically
due to the agent’s broad antimicrobial activity. It is ef-
fective after oral administration for the treatment of a
wide variety of infectious diseases (Petri, 2001:1182).
Side effects of ciprofloxacin
Fluoroquinolones are generally well-tolerated. The most
common adverse reactions involve the gastrointestinal
tract (nausea, vomiting and/or abdominal discomfort
reported by 3% to 17% of the patients). Central ner-
vous system side-effects, predominantly mild headache
and dizziness have been reported in 0.9% to 11% of
patients. Skin rashes, including photosensitivity reac-
tions (sensitivity of the skin to direct sunlight), may
occur. Allergic reactions have been described, such as
hives (urticaria) and anaphylaxis (Petri, 2001:1182).
Three cases of anaphylactic reactions (a rate of about
1:1000, much higher than the 1:100 000 quoted) were
reported in approximately 3200 first-year university stu-
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dents who accepted single dose ciprofloxacin 500 mg
as prophylactic treatment (Burke & Burne, 2000:679).
Side-effects reported by naval training personnel after
receiving a single dose of oral ciprofloxacin 500 mg
were mild in nature with the exception of one recipient
who developed an acute urticarial reaction ten minutes
after taking the tablet (Gaunt & Lambert, 1988:493).
Quinolones and fluoroquinolones cause arthralgias (pain
in joints) and joint swelling in children receiving
ciprofloxacin and are, for that reason, not recommended
for use in pre-pubertal children or pregnant women.
Leucopoenia, eosinophilia and mild elevations in se-
rum transaminase rarely occur (Petri, 2001:1182).
Many antibiotics, including ciprofloxacin, can alter the
normal bacteria in the colon and encourage overgrowth
of bacteria responsible for the development of inflam-
mation of the colon (pseudomembranous colitis), caus-
ing fever, abdominal pain, diarrhoea, and sometimes
even shock (Petri, 2001:1182).
STUDY METHOD
Research Design and Setting
An open non-randomised study was conducted, based
on a voluntary and anonymous questionnaire distrib-
uted in Afrikaans, English and Setswana (refer to ad-
dendum) on 31 July 2003 (three days after mass pro-
phylaxis) to students and staff of the PU for CHE. It
was decided to target the maximum possible number
of participants by posting the questionnaire electroni-
cally on the bulletin board of the PU for CHE. In addi-
tion, 3500 printed copies were distributed as follows:
a) to the respective House Committee represen-
tatives of all residences on and off campus;
b) to two libraries (left at the entrances of the li-
braries) on campus; and
c) to various departments to include all the work-
ers employed in the kitchens, gardens and
hostels together with possible subcontractor
workers at that time.
The questionnaire had to be returned on or before 6
August, 2003.
Study Population
A total of  9 075 single prophylactic doses of
ciprofloxacin 500 mg tablets were dispensed to staff
and students of the PU for CHE as follows:
a)  prior to 28 July 2003 (direct contacts to positively
diagnosed cases): 539 single doses;
b)  mass issue on 28 July 2003: 8 525 single doses;
c)  issue on 29 July 2003 (to staff and students not
available on 28 July 2003): 11 single doses;
d)  9075 Single doses of ciprofloxacin 500 mg were
issued;
e)  1 537 individuals (16.9%) voluntarily completed ques-
tionnaires and returned them to the Department of Phar-
macology before or on the set due date (Joint Task
Team: Provincial and Local Health Authorities and PU
for CHE, 2003c).
Validity and Reliability
The following actions were taken in order to ensure the
reliability and validity (face and content) of the ques-
tions in the questionnaire:
a)  special attention was given to ensure that each ques-
tion only implied one concept; and
b)  different preliminary versions of the questionnaire
were drawn up and evaluated by various experts in the
field of pharmacology, pharmacy practise and statis-
tics.
An application for approval of the study was submitted
to the Ethics Committee of the PU for CHE and to the
Department of Health, North-West Province and both
approved the study.
Statistical Analysis
The SAS System for Windows (SAS Institute, 2001)
was used to create the database and to analyse the
data by calculating certain descriptive and inferential
statistics. The descriptive statistics included frequency
tables, histograms and percentage expressions. Chi-
square tests (χ2) were used as inferential statistics to
determine whether a difference existed between the
side-effects reported by the participants who received
only a single dose versus  the participants who received
multiple dose ciprofloxacin 500 mg; single dose versus
gender effect, multiple dose versus  gender effect and
single dose-gender versus consultation required.
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Because the responses were voluntary, the participants
were not randomly selected. As a result, the following
equation and guidelines were used to interpret the prac-





where (χ2) is the usual Chi-square statistic for a two-
way frequency table and n = number of participants.
The guidelines used to interpret the results followed
the criteria provided by Cohen (1988:227):
w = 0.1 small effect (non significant)
w = 0.3 (medium effect)
w = 0.5 large effect (significant and of practical
importance)
RESULTS AND DISCUSSIONS
Table 2 indicates that 1537 questionnaires were re-
ceived from voluntary participants. Table 2 reflects the
general demographic details of the participants. Table
4 reflects that 51.4% (741) of the participant (N=1443.94
missing data) indicated that they took a  single dose
treatment and 48.6% (702) indicated that they took more
than one dose of ciprofloxacin 500 mg during the time
period 25 - 29 July 2003. The female participants repre-
sented 65.4% (N = 731, 10 missing data) and the male
participants represented 34.6% of the voluntary single
dose study population.
The data reflected in Table 3 indicate the frequencies
and percentages of all the side-effects reported by the
participants (expressed as a percentage of 741 partici-
pants) who indicated that they took a single dose of
ciprofloxacin 500 mg.  All the responses of the partici-
pants (staff; on-campus students; and off-campus stu-
dents) were combined and the gender contributions are
reflected.
The data in Figure 1 indicate the percentage of side-
effects greater than 1%, as reported by the participants
who indicated that they took a single dose of
ciprofloxacin 500 mg (expressed as a percentage of
741 participants). These side-effects included headache
(9.3%), nausea (8.5%), sleepiness (8.0%), dizziness
(5.9%), stomach cramps (4.6%), listlessness (3.4%),
trembling (2.2%), insomnia (1.8%), diarrhoea (1.4%),
itchiness (1.2%) and heart palpitations (1.1%).
Table 4 comprises comparative data with respect to
the number of participants who experienced side-ef-
fects due to single dose versus multiple doses and the
number of participants who consulted a healthcare
worker due to the side-effect(s) they experienced. It is
indicated that 392 (25.5%) of the 1537 participants (295
females or 19.2% and 97 males or 6.3%) reported one
or more side effects. Of these 392 participants, 179
participants (11.6%) indicated that they took a single
dose and 189 (12.3%) participants indicated that they
took more than one dose of ciprofloxacin (24 (1.6%)
participants did not indicate their dosage).
Of the 1537 participants 78 (5.1%), 40 on a single dose
and 36 on multiple doses, (two did not indicate their
dosages) indicated that they had to consult a healthcare
worker about the side-effects experienced as a result
of taking ciprofloxacin.
The side-effects for which further medical consultation
was required after single dose ciprofloxacin 500 mg
are shown in Figure 2. These side-effects are also ex-
pressed as a percentage of 741 single dose partici-
pants, constituting headache (2.0%), nausea (1.9%),
dizziness (1.8%), sleepiness (1.5%), stomach cramps
(0.9%), listlessness (0.7%), diarrhoea (0.54%), trem-
bling (0.54%), insomnia (0.4%), heart palpitations
(0.4%), vomiting (0.3%), convulsions (0.3%), skin rash
(0.3%), visual disturbances (0.1%), joint pains (0.1%),
redness of skin (0.1%), itchiness (0.1%), tiredness
(0.1%), cold and flu symptoms (0.1%), neck pain/stiff-
ness (0.1%), hypertension (0.1%), sore throat (0.1%)
and fever (0.1%). Headache, nausea, dizziness and
sleepiness were thus the only side-effects reported with
a prevalence of greater than 1% after administration of
a single dose of ciprofloxacin 500mg for which further
medical consultation was required.
The SAS-calculated Chi-square-values (χ 2)
for all the various side-effects due to a single dose, and
those due to multiple doses, were used in the effect
size equation to establish whether the effects experi-
enced were significant. None of the w-values reached
significance.  The effect of gender was tested on the
different side-effects reported with a single dose as well
as with the side-effects reported after ingestion of mul-
tiple doses. Once again, no significance due to gender
differences could be shown for any of the side-effects.
The effect size tested to measure the relationship be-
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Table 2: Demographic details of all voluntary participants
A= The participants indicated as “others” are family members (children and spouses) of staff members who also completed the question-
naire by choice.
B= 13 participants indicated that they were students (off-campus and on-campus) but did not indicate their gender.
C= 26 participants did not indicate where they received their treatment.
D= 94 participants did not reply to this section by indicating whether or not they took a single or multiple dose.
tween the side-effects due to a single dose, gender or
causing consultation requirement with a health care
worker, also indicated no practical significance. These
results are not included, as no significance could be
shown.
The information obtained through this questionnaire on
possible drug interactions and the effect thereof on
greater side-effect prevalence was not included in the
scope of this article but the data is available for further
statistical analysis.
Limitation of the study
In order to obtain a reliable response in the shortest
possible time following the outbreak and accompany-
ing prophylactic treatment, the design and execution
of the study were somewhat complicated by the high
level of social fear surrounding the outbreak.  As a result,
the decision to conduct this investigation was only made
after the mass prophylaxis exercise had been
completed. Therefore, the opportunity to issue the
questionnaire simultaneously with the medication was
lost, which could have impacted negatively on the
response rate. However, in support of the method used
the possibility of perceived side-effects being reported
was eliminated.
CONCLUSIONS
One of the main aims of this study was to investigate
the prevalence of side-effects after the administration
of a single dose of ciprofloxacin 500 mg. It is apparent
from the data analysis of the 1537 voluntary partici-
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Table 3: Frequencies and percentages of all the side-effects reported (SINGLE DOSE)
Table 4: Comparative data of side-effects reported or medical consultation required after single dose or
multiple dose administration
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Nausea Vomiting Stomach cramps Diarrhoea
Vision Disturbances Dizziness Headache Convulsions
Listlessness Sleepiness Insomnia Trembling
Heart palpitations Joint pains Skin rash Redness of skin
Itchiness Tiredness Cold & Flu Neck stiffness/pain
Hypertension Sore throat/irritation Fever
Figure 2: Percentage of the side-effects for which consultation was required (Single Dose)
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pants that only 51.4% (n=1443,94 missing data) of the
participants took a single dose of ciprofloxacin 500 mg.
The remaining 48,6% took more than one dose of
ciprofloxacin 500 mg.
The total percentage of participants who reported side-
effects was 25.5% (392 participants) of the 1537 volun-
tary participants, but this included both the single dose
and multiple dose groups. Side-effects resulting from
multiple doses compared to side-effects resulting from
a single dose did not indicate any practical significance.
The side-effects reported by the single dose partici-
pants were 24.2% (expressed as a percentage of the
total number of participants, 741, on single dose only)
and by the multiple dose participants 26.9% (expressed
as a percentage of the total number of participants,
702, multiple doses).
The participants requiring further medical consultation
due to the severity of their side-effects after a single
dose of ciprofloxacin 500 mg totalled 5.4% (expressed
as a percentage of 741 participants). When the effect
size (w) was calculated and compared to the guide-
lines as provided by Cohen (1988) no practically sig-
nificant relationship was shown for any of the side-ef-
fects reported on single dose, multiple doses, nor when
the effects of gender or requirement for medical con-
sultation were tested.
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ADDENDUM:
VOLUNTARY QUESTIONNAIRE WITH REGARD TO THE
MENINGITIDIS PREVENTATIVE PROJECT
Dear Staff member / Student
In light of the current events the last couple of weeks
concerning the meningitis outbreak in Potchefstroom, the
pharmacologists and pharmacists of the School of
Pharmacy of PU for CHE request your cooperation with
the completion of the following questionnaire.  The
prophylactic medication used was ciprofloxacin 500 mg
(also known as Ciprobay ; Adco-Cifrin ; Cifloc ; Cifran )
provided to you as a single dose on 28 July 2003. Children
would have received according to their age smaller doses
of ciprofloxacin or even rifampicin as supplied by retail
pharmacies; state hospitals or clinics. Ciprofloxacin is
currently accepted worldwide as the most suitable oral
drug for prophylaxis of Neisseria meningitidis in adults,
despite several possible side effects as described in the
pharmacological literature.  We are of the opinion that you
can assist us to obtain useful information regarding the
actual side-effects of a single ciprofloxacin dose, as
experienced by this specific target population.  Information
gained from the Potchefstroom experience may be
valuable in future - not only for Potchefstroom residents,
but also for the management of similar outbreaks in other
communities.  Your friendly and voluntary cooperation in
completing this questionnaire is therefore much
appreciated.  All information will be treated confidentially.
Please mark the relevant space clearly with a cross (x)
and provide more detailed information only when
requested.  If a specific question is not relevant just ignore
it.
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